European Journal of Clinical Pharmacology

, Volume 68, Issue 11, pp 1493–1499 | Cite as

Association of UDP-glucuronosyltransferase 1A9 polymorphisms with adverse reactions to catechol-O-methyltransferase inhibitors in Parkinson’s disease patients

  • Marco Ferrari
  • Emilia Martignoni
  • Fabio Blandini
  • Giulio Riboldazzi
  • Giorgio Bono
  • Franca Marino
  • Marco Cosentino



To investigate the association between adverse reactions to catechol-O-methyltransferase (COMT) inhibitors and the UDP-glucuronosyltransferase 1A9 genotypes UGT1A9*1b and UGT1A9*3a, which were previously identified in individual cases of COMT inhibitor-induced toxicity.


The study included 52 Parkinson’s disease (PD) patients on COMT inhibitors without evidence of adverse reactions and 11 PD patients who had been withdrawn from COMT inhibitors due to adverse reactions. UGT1A9*1b was identified by direct sequencing of the PCR amplification of the gene and UGT1A9*3a was assayed by real-time PCR.


The frequency of the *3a/*3a and *1/*3a genotype variants was 45.5 % in subjects with adverse reactions and 21.1 % in subjects without adverse reactions [overall UGT1A9*3a allele frequency 27.3 vs. 11.5 %, P = 0.087; odds ratio (OR) 2.87, 95 % confidence interval (CI) 0.94–8.77]. The frequency of genotype combinations leading to low glucuronosyltransferase activity (*3a/*3a irrespective of *1b or *1/*3a and *1/*1b) was 5.8 % in subjects without adverse reactions and 36.4 % in subjects with adverse reactions (P = 0.014; OR 9.33, 95 % CI 1.71–50.78).


In PD patients UDP-glucuronosyltransferase 1A9 genotypes are associated with adverse reactions to COMT inhibitors, leading to treatment withdrawal. UDP-glucuronosyltransferase 1A9 genotyping may be a screening and/or diagnostic test to assist individualized treatments with COMT inhibitors.


UGT1A9 Catechol-O-methyltransferase inhibitors Adverse reactions Parkinson’s disease 


  1. 1.
    Bonifácio MJ, Palma PN, Almeida L, Soares-da-Silva P (2007) Catechol-O-methyltransferase and its inhibitors in Parkinson's disease. CNS Drug Rev 13:352–379PubMedCrossRefGoogle Scholar
  2. 2.
    Kaakkola S (2010) Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson’s disease. Int Rev Neurobiol 95:207–225PubMedCrossRefGoogle Scholar
  3. 3.
    Fisher A, Croft-Baker J, Davis M, Purcell P, McLean AJ (2002) Entacapone-induced hepatotoxicity and hepatic dysfunction. Mov Dis 17:1362–1365CrossRefGoogle Scholar
  4. 4.
    Martignoni E, Cosentino M, Ferrari M, Porta G, Mattarucchi E, Marino F, Lecchini S, Nappi G (2005) Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism. Neurology 65:1820–1822PubMedCrossRefGoogle Scholar
  5. 5.
    Lautala P, Ethell BT, Taskinen J, Burchell B (2000) The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos 28:1385–1389PubMedGoogle Scholar
  6. 6.
    Acuña G, Foernzler D, Leong D, Rabbia M, Smit R, Dorflinger E, Gasser R, Hoh J, Ott J, Borroni E, To Z, Thompson A, Li J, Hashimoto L, Lindpaintner K (2002) Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity. Pharmacogenomics J 2:327–334PubMedCrossRefGoogle Scholar
  7. 7.
    Yamanaka H, Nakajima M, Katoh M, Hara Y, Tachibana O, Yamashita J, McLeod HL, Yokoi T (2004) A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics 14:329–332PubMedCrossRefGoogle Scholar
  8. 8.
    Villeneuve L, Girard H, Fortier LC, Gagné JF, Guillemette C (2003) Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther 307:117–128PubMedCrossRefGoogle Scholar
  9. 9.
    Gibb WRG, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51:745–752PubMedCrossRefGoogle Scholar
  10. 10.
    Kang TK, Ensom MH, Chang TK (2005) UDP-glucuronosyltransferases and clinical drug–drug interactions. Pharmacol Ther 106:97–132PubMedCrossRefGoogle Scholar
  11. 11.
    Edwards IR, Biriell C (1994) Harmonisation in pharmacovigilance. Drug Safety 10:93–102PubMedCrossRefGoogle Scholar
  12. 12.
    Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 25:2649–2653PubMedCrossRefGoogle Scholar
  13. 13.
    Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, Jang IJ, Lee DH, Lee JS (2006) Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24:2237–2244PubMedCrossRefGoogle Scholar
  14. 14.
    Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, Rogatko A, Wang H, Blanchard RL (2005) UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 11:1226–1236PubMedGoogle Scholar
  15. 15.
    Huang SH, Chao Y, Wu YY, Luo JC, Kao CH, Yen SH, Li CP (2011) Concurrence of UGT1A polymorphism and end-stage renal disease leads to severe toxicities of irinotecan in a patient with metastatic colon cancer. Tumori 97:243–247PubMedGoogle Scholar
  16. 16.
    Cecchin E, Innocenti F, D'Andrea M, Corona G, De Mattia E, Biason P, Buonadonna A, Toffoli G (2009) Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol 27:2457–2465PubMedCrossRefGoogle Scholar
  17. 17.
    Martinez-Balibrea E, Abad A, Martínez-Cardús A, Ginés A, Valladares M, Navarro M, Aranda E, Marcuello E, Benavides M, Massutí B, Carrato A, Layos L, Manzano JL, Moreno V (2010) UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. Br J Cancer 103:581–589PubMedCrossRefGoogle Scholar
  18. 18.
    Bernard O, Guillemette C (2004) The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos 32:775–778PubMedCrossRefGoogle Scholar
  19. 19.
    Lévesque E, Delage R, Benoit-Biancamano MO, Caron P, Bernard O, Couture F, Guillemette C (2007) The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ther 81:392–400PubMedCrossRefGoogle Scholar
  20. 20.
    Jain L, Woo S, Gardner ER, Dahut WL, Kohn EC, Kummar S, Mould DR, Giaccone G, Yarchoan R, Venitz J, Figg WD (2011) Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharmacol 72:294–305PubMedCrossRefGoogle Scholar
  21. 21.
    Nakamura A, Nakajima M, Yamanaka H, Fujiwara R, Yokoi T (2008) Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos 36:1461–1464PubMedCrossRefGoogle Scholar
  22. 22.
    Strassburg CP, Oldhafer K, Manns MP, Tukey RH (1997) Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Mol Pharmacol 52:212–220PubMedGoogle Scholar
  23. 23.
    Jorga KM, Fotteler B, Heizmann P, Gasser R (1999) Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase. Br J Clin Pharmacol 48:513–520PubMedCrossRefGoogle Scholar
  24. 24.
    Wikberg T, Vuorela A, Ottoila P, Taskinen J (1993) Identification of major urinary metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. Drug Metab Dispos 21:81–92PubMedGoogle Scholar
  25. 25.
    European Medicines Agency (2010) Comtan—product information. Last updated: 30/09/2010. Available at: Accessed 15 Dec 2011
  26. 26.
    European Medicines Agency (2010) Stalevo—product information. Last updated: 15/12/2010. Available at: Accessed 15 Dec 2011
  27. 27.
    Winge K, Fowler CJ (2006) Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord 21:737–745PubMedCrossRefGoogle Scholar
  28. 28.
    Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA (1982) Evaluating the yield of medical tests. JAMA 247:2543–2546PubMedCrossRefGoogle Scholar
  29. 29.
    McGee S (2002) Simplifying likelihood ratios. J Gen Intern Med 17:646–649PubMedCrossRefGoogle Scholar
  30. 30.
    Thibaudeau J, Lépine J, Tojcic J, Duguay Y, Pelletier G, Plante M, Brisson J, Têtu B, Jacob S, Perusse L, Bélanger A, Guillemette C (2006) Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res 66:125–133PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Marco Ferrari
    • 1
  • Emilia Martignoni
    • 2
  • Fabio Blandini
    • 3
  • Giulio Riboldazzi
    • 2
  • Giorgio Bono
    • 1
  • Franca Marino
    • 1
  • Marco Cosentino
    • 1
  1. 1.Center for Research in Medical PharmacologyUniversity of InsubriaVareseItaly
  2. 2.Department of Clinical Medicine, Section of NeurologyUniversity of InsubriaVareseItaly
  3. 3.Interdepartmental Research Center for Parkinson’s DiseaseIRCCS Neurological Institute “C. Mondino”PaviaItaly

Personalised recommendations